Certara Launches Non-Animal Navigator For Drug Development

Certara Inc. has launched its Non-Animal Navigator™ solution, designed to assist biopharmaceutical companies in aligning with the FDA's Roadmap to Reducing Animal Testing in Preclinical Safety Studies. This new initiative leverages AI-enabled biosimulation and aims to enhance drug development by integrating various data sources, thus reducing costs and speeding up timelines. The solution includes strategic regulatory advice, an integrated preclinical development plan, and advanced modeling tools like the Simcyp Simulator®, aimed at ensuring compliance with evolving regulatory standards. Certara's long-standing collaboration with health authorities adds credibility to this innovative approach, which targets monoclonal antibodies and antibody-drug conjugates, areas identified as ripe for alternative testing methods. The launch reflects a broader industry trend towards ethical drug development practices and positions Certara favorably in the competitive landscape. CEO William F. Feehery emphasized the potential for this shift to improve strategic decision-making and overall success rates in drug development.